BDX

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2003 (First Quarter of Fiscal 2004) for Becton, Dickinson and Company (BD). BD is a medical technology company operating through three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company reported 252,705,484 shares of common stock outstanding as of January 31, 2004.

Key Financial Metrics

Note: Total Debt calculated as Short-term debt ($10,504,000) + Long-term debt ($1,164,923,000). Debt-to-capitalization ratio was 27.2% at period end.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 14% year-over-year. Organic growth (excluding foreign currency) was 7%. International revenues grew 23% reported, or 9% excluding currency effects.
• Segment Performance:
  • Medical: Revenues up 10% (3% organic). Operating income declined to $92 million from $123 million due to a $45 million charge related to blood glucose monitoring (BGM) products.
  • Diagnostics: Revenues up 21% (15% organic). Operating income rose to $98 million from $66 million, driven by strong sales of respiratory/flu tests and the BD ProbeTec ET system.
  • Biosciences: Revenues up 16% (8% organic). Operating income increased to $30 million from $19 million.
• Margin Impact: Gross profit margin decreased 110 basis points to 46.6%, primarily due to the $45 million BGM charge which reduced margin by 370 basis points. This was partially offset by higher-margin safety-engineered product sales.
• Liquidity: Operating cash flow nearly doubled to $213 million compared to $114 million in the prior year, which had been reduced by a $100 million pension contribution.

Guidance, Outlook, and Risks

• Unusual Items: The company recorded a pre-tax charge of $45.0 million in Cost of Products Sold. This included a $6.5 million reserve for a voluntary recall of BGM test strips, a $29.8 million write-off of non-conforming inventory, and an $8.7 million write-off of assets related to discontinuing the BD Latitude system in the U.S.
• Outlook: Management expects U.S. safety-engineered device sales to grow 10% to 15% annually over the next several years. Capital spending for fiscal 2004 is expected to be approximately $300 million. The effective tax rate for fiscal 2004 is expected to be approximately 24%.
• Risks and Contingencies:
  • Legal Proceedings: BD is involved in various litigation, including 524 latex allergy claims (386 closed with no liability) and patent infringement suits (e.g., RTI Litigation, Greiner suit in UK). Management believes outcomes will not be material but acknowledges uncertainty.
  • Regulatory/Market: Risks include healthcare cost containment, pricing pressures, and potential impacts from the SARS epidemic.
  • Accounting Changes: The company is evaluating the impact of FIN 46 (Variable Interest Entities) effective March 31, 2004, but does not expect a material impact.

Investor Verification Checklist

• Verify the sustainability of revenue growth in the Diagnostics segment, specifically regarding respiratory and flu test sales which may be seasonal or pandemic-driven.
• Confirm the extent of the BGM product recall and the timeline for the transition to the BD Logic and Paradigm Link systems.
• Monitor the status of pending litigation, particularly the RTI patent case and the Greiner suit in the UK, for potential future charges.
• Review the company's ability to maintain gross margins as the mix shifts toward safety-engineered devices and as the one-time BGM charge is excluded from future periods.
• Assess the impact of foreign currency fluctuations on international revenue growth, which contributed significantly to the reported 23% increase.